Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (clinicaltrials.gov) - Jun 30, 2026 - P3 | N=27 | Active, not recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2026 ➔ Sep 2026
Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|